Top 20 of Myocardial Infarction

Article title # Publications/# Citations

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

2002: Writing Group for the Women's Health Initiative Investigators; GLAnderson; SABeresford; BVHoward; RDJackson; KCJohnson; CKooperberg; JMKotchen; ... AZLaCroix; JOckene; RLPrentice; JERossouw; MLStefanick;

1331

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

2004 Sep 11-17: INTERHEART Study Investigators; AAvezum; ABudaj; TDans; SHawken; FLanas; LLisheng; MMcQueen; ... SOunpuu; PPais; JVarigos; SYusuf;

743

Inflammation, atherosclerosis, and coronary artery disease.

2005: GKHansson;

723

Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

1996:

687

Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.

1986: RBJennings; CEMurry; KAReimer;

621

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1994:

593

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

2002: Heart Protection Study Collaborative Group;

588

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

2000: AIAdler; CACull; DHadden; RRHolman; SEManley; DRMatthews; HANeil; IMStratton; RCTurner;

578

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

2008: JUPITER Study Group; EDanielson; FAFonseca; JGenest; RJGlynn; AMGotto; JJKastelein; WKoenig; ... PLibby; AJLorenzatti; JGMacFadyen; BGNordestgaard; PMRidker; JShepherd; JTWillerson;

569

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.

2000: JBosch; GDagenais; RDavies; JPogue; PSleight; SYusuf;

563

Bone marrow cells regenerate infarcted myocardium.

2001: SMAnderson; PAnversa; DMBodine; SChimenti; IJakoniuk; JKajstura; ALeri; BLi; ... RMcKay; BNadal-Ginard; DOrlic; JPickel;

558

10-year follow-up of intensive glucose control in type 2 diabetes.

2008: MABethel; RRHolman; DRMatthews; HANeil; SKPaul;

545

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

1998: SMHaffner; MLaakso; SLehto; KPyörälä; TRönnemaa;

532

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

2005: Cholesterol Treatment Trialists' (CTT) Collaborators; CBaigent; LBlackwell; GBuck; RCollins; PMKearney; AKeech; AKirby; ... RPeto; CPollicino; RSimes; TSourjina;

531

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

2007: SENissen; KWolski;

528

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

1998:

523

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

2004: American College of Cardiology Foundation; American Heart Association; National Heart, Lung, and Blood Institute; HBBrewer; LTClark; JICleeman; SMGrundy; DBHunninghake; ... CNMerz; RCPasternak; SCSmith; NJStone;

516

Adult cardiac stem cells are multipotent and support myocardial regeneration.

2003: PAnversa; MBaker; LBarlucchi; APBeltrami; SChimenti; JKajstura; HKasahara; ALeri; ... FLimana; EMusso; BNadal-Ginard; MRota; DTorella; KUrbanek;

499

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

1995: SMCobbe; IFord; CGIsles; ARLorimer; PWMacfarlane; JHMcKillop; CJPackard; JShepherd;

483

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

1996: JMArnold; EBraunwald; LBrown; TGCole; BRDavis; LAMoyé; MAPfeffer; JLRouleau; ... JDRutherford; FMSacks; JWWarnica; CCWun;

450